Company profile
Alveron Pharma company profile
Alveron Pharma develops treatment for hemorrhagic stroke, a severe unmet medical need. Alveron’s drug OKL-1111 strongly reduces hematoma expansion in a mouse model of intracranial hemorrhage. As an injection solution that is ready to use, OKL-1111 is being developed to do away with a laborious pre-treatment process.
Business identity
- Website
- http://www.alveron.com/
- Contact email
- [email protected]
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 1-10 employees
- Revenue range
- $0-$1M
- Founded
- 2011-01-01
Headquarters
- Headquarters
- Nijmegen, Gelderland, The Netherlands
- Country code
- NL
- Continent
- Europe